Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Operating Expenses (2017 - 2025)

Historic Operating Expenses for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $20.4 million.

  • Aclaris Therapeutics' Operating Expenses rose 3800.36% to $20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $169.1 million, marking a year-over-year increase of 13037.76%. This contributed to the annual value of $160.7 million for FY2024, which is 2491.8% up from last year.
  • Latest data reveals that Aclaris Therapeutics reported Operating Expenses of $20.4 million as of Q3 2025, which was up 3800.36% from $20.2 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Operating Expenses registered a high of $108.9 million during Q4 2024, and its lowest value of $14.8 million during Q3 2024.
  • Moreover, its 5-year median value for Operating Expenses was $22.0 million (2021), whereas its average is $29.8 million.
  • The largest annual percentage gain for Aclaris Therapeutics' Operating Expenses in the last 5 years was 40370.54% (2024), contrasted with its biggest fall of 6373.63% (2024).
  • Quarter analysis of 5 years shows Aclaris Therapeutics' Operating Expenses stood at $24.4 million in 2021, then skyrocketed by 50.99% to $36.8 million in 2022, then plummeted by 41.31% to $21.6 million in 2023, then surged by 403.71% to $108.9 million in 2024, then plummeted by 81.22% to $20.4 million in 2025.
  • Its Operating Expenses stands at $20.4 million for Q3 2025, versus $20.2 million for Q2 2025 and $19.5 million for Q1 2025.